Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PRAVEEN KUMAR TUMULA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1447402896
CMS profile
746364
Location
AMARILLO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$1,916.32

26 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $1,310.00 2
Food and Beverage $426.34 22
Education $179.98 2

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PRAVEEN KUMAR TUMULA

NPI 1447402896 · CMS profile ID 746364

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

AMARILLO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447402896?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PRAVEEN KUMAR TUMULA, NPI 1447402896, CMS profile ID 746364. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447402896?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). PRAVEEN KUMAR TUMULA, NPI 1447402896, CMS profile ID 746364. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447402896?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
PRAVEEN KUMAR TUMULA, NPI 1447402896, CMS profile ID 746364, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1447402896?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

26 matching records · $1,916.32 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 26 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–26 of 26.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Tactile Systems Technology Inc $12.9811/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 873564863 CMS
GENZYME CORPORATION $17.8011/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939023745 CMS
E.R. Squibb & Sons, L.L.C. $300.0011/08/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932667857 CMS
PFIZER INC. $20.2810/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949498073 CMS
PUMA BIOTECHNOLOGY, INC. $13.2610/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942296183 CMS
CTI BioPharma Corp. $17.4410/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933546685 CMS
E.R. Squibb & Sons, L.L.C. $2.1109/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932667777 CMS
ADC Therapeutics America, Inc. $23.4109/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 922063799 CMS
Janssen Scientific Affairs, LLC $31.1608/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887265757 CMS
E.R. Squibb & Sons, L.L.C. $5.9808/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932667751 CMS
Seagen Inc. $22.1407/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904126005 CMS
Novartis Pharmaceuticals Corporation $16.8605/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894426163 CMS
Incyte Corporation $16.3305/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943028633 CMS
Abbott Laboratories $22.4405/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914208065 CMS
Adaptive Biotechnologies Corporation $26.7505/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951434581 CMS
Medtronic, Inc. $14.6204/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930725243 CMS
PUMA BIOTECHNOLOGY, INC. $14.5504/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942288761 CMS
Seagen Inc. $99.9904/12/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904126001 CMS
Seagen Inc. $89.7204/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904126003 CMS
E.R. Squibb & Sons, L.L.C. $14.8304/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932667711 CMS
Janssen Scientific Affairs, LLC $1,010.0004/04/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887265750 CMS
Tactile Systems Technology Inc $17.4304/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 873564861 CMS
E.R. Squibb & Sons, L.L.C. $3.8403/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932667699 CMS
E.R. Squibb & Sons, L.L.C. $19.6503/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932667701 CMS
Epizyme, Inc., $79.9902/04/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917612491 CMS
E.R. Squibb & Sons, L.L.C. $2.7601/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932667829 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,168.66 28
PY2020 $4,815.65 8
PY2021 $340.16 6
PY2022 $1,916.32 26
PY2023 $4,540.57 16
PY2024 $2,679.61 6
PY2025 $6,258.84 11

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $604,557.82 36
PY2024 Principal investigator $1,085,444.24 161
PY2023 Principal investigator $684,815.25 77
PY2022 Principal investigator $638,195.90 127
PY2021 Principal investigator $416,830.90 164
PY2020 Principal investigator $201,522.62 122
PY2019 Recipient $1,287.72 1
PY2019 Principal investigator $54,363.67 98

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $4,998.00 12/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211681158
Principal investigator 1 Genentech, Inc. $4,998.00 12/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211681164
Principal investigator 1 BeOne Medicines Ltd. $9,220.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335087
Principal investigator 1 BeOne Medicines Ltd. $8,702.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335092
Principal investigator 1 BeOne Medicines Ltd. $9,220.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335100
Principal investigator 1 BeOne Medicines Ltd. $497.06 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335104
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $10,881.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 No dispute reported 06/30/2026 1235993799
Principal investigator 1 BeOne Medicines Ltd. $1,125.00 11/18/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335096
Principal investigator 1 BeOne Medicines Ltd. $1,125.00 11/18/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335108
Principal investigator 1 BeOne Medicines Ltd. $1,125.00 11/18/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335114
Principal investigator 1 BeOne Medicines Ltd. $1,125.00 11/18/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335117
Principal investigator 1 Epizyme, Inc. $1,125.00 11/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281610
Principal investigator 1 Genentech, Inc. $1,125.00 11/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211681116
Principal investigator 1 Genentech, Inc. $1,125.00 11/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211681134
Principal investigator 1 BeOne Medicines Ltd. $1,125.00 10/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335121
Principal investigator 1 BeOne Medicines Ltd. $1,125.00 10/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335126
Principal investigator 1 Novartis Pharmaceuticals Corporation $985.00 10/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY EL PASO CANCER TREATMENT CENTER GATEWAY
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase No dispute reported 06/30/2026 1190302071
Principal investigator 1 Epizyme, Inc. $1,125.00 09/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281478
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $103.50 09/03/2025 Non-covered Recipient Entity
Us Oncology Research
A Phase 3b randomized study of lenalidomide (CC-5013)plus rituximab maintenance therapy followed by lenalidomide singe-agent maintenance vs. rituximab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma No dispute reported 06/30/2026 1235992121
Principal investigator 1 Genentech, Inc. $2,594.00 07/11/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211680321
Principal investigator 1 Genentech, Inc. $1,125.00 07/09/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211680295
Principal investigator 1 BeOne Medicines Ltd. $1,125.00 06/17/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190331319
Principal investigator 1 Celgene Corporation $7,120.00 05/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute Llc
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 No dispute reported 06/30/2026 1222306847
Principal investigator 1 Genentech, Inc. $1,125.00 04/25/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211679983
Principal investigator 1 Genentech, Inc. $1,125.00 04/25/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211680003
Principal investigator 1 Genentech, Inc. $1,125.00 04/25/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211680051
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,317.00 04/15/2025 Non-covered Recipient Entity
Texas Onco Southwest Fort Worth
Phase 3b, Open-label study evaluating the efficacy and safety of luspatercept (BMS-986346/ACE-536) initiated at maximum approved dose in LR-MDS with IPSS-R very low, low or intermediate risk who require RBC transfusions No dispute reported 06/30/2026 1235993245
Principal investigator 1 Celgene Corporation $375.00 04/09/2025 Non-covered Recipient Entity
Texas Onco Southwest Fort Worth
Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. No dispute reported 06/30/2026 1222304639
Principal investigator 1 Celgene Corporation $59,284.00 04/04/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 No dispute reported 06/30/2026 1222305468
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $83,641.00 04/02/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
Phase 3b, Open-label study evaluating the efficacy and safety of luspatercept (BMS-986346/ACE-536) initiated at maximum approved dose in LR-MDS with IPSS-R very low, low or intermediate risk who require RBC transfusions No dispute reported 06/30/2026 1235993797
Principal investigator 1 Genentech, Inc. $17,750.00 04/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211679977
Principal investigator 1 Genentech, Inc. $70.00 04/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211680237
Principal investigator 1 Genentech, Inc. $1,297.00 01/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211679899
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $19,519.00 01/15/2025 Non-covered Recipient Entity
Texas Onco Southwest Fort Worth
Phase 3b, Open-label study evaluating the efficacy and safety of luspatercept (BMS-986346/ACE-536) initiated at maximum approved dose in LR-MDS with IPSS-R very low, low or intermediate risk who require RBC transfusions No dispute reported 06/30/2026 1235993243
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,662.98 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY EL PASO CANCER TREATMENT CENTER GATEWAY
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase No dispute reported 06/30/2026 1190302069
Principal investigator 1 Novartis Pharmaceuticals Corporation $334,448.28 01/09/2025 Non-covered Recipient Entity
TEXAS ONCO AMARILLO
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase No dispute reported 06/30/2026 1190298308